Snapshot from Apr 21, 2026 at 07:00 UTC. For live data and tracking: View Live
Entities / Incyte
Company

Incyte

Tracked across 1 events · 9 articles · First seen Jan 30, 2026 · Last active Mar 06, 2026

Sentiment
70
Attention
4
Events
1
Relationships
2
Live sentiment trends, attention charts, and prominence tracking available on the NewsDesk Dashboard
Events (1)
4 70
Business
European Commission Approves Incyte's Retifanlimab for SCAC
Incyte received European Union===European Commission approval for Retifanlimab in combination with chemotherapy for first-line treatment of metastatic or inoperable locally recurrent squamous cell carcinoma of the anal canal. This expands their product portfolio and market reach in Europe, positively impacting their stock price and reputation.
Jan 30, 2026 · 9 articles
Relationships (2)
MacroGenics licensee ↔ Incyte Incyte holds global rights to Retifanlimab through a license agreement with Macr
Bill Meury CEO ↔ Incyte Bill Meury is the President and Chief Executive Officer of Incyte.
NEWSDESK
Track Incyte live

Set up alerts, explore relationships, view sentiment trends, and monitor how events impact this entity in real time.

Open Dashboard

About NewsDesk

NewsDesk is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.newsdesk.dev.